News
News
Current position:News > News
News
Genomeditech has officially secured global commercial usage rights for HEK293, Jurkat, and CHO-K1 cell lines
Genomeditech now holds global commercial usage rights for HEK293, Jurkat, and CHO-K1 cell lines. These widely used cell lines are essential for research and development in the biopharmaceutical industry. With clear traceability and legal compliance, Genomeditech is helping simplify authorization and accelerate commercialization. Learn more about the advantages and solutions we provide.
2026-06-03
cMET:U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
2025-05-15
FGF21:GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD
2025-05-15
FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
2025-04-25
GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
2025-04-25
DLL4 Breakthrough in Cancer Therapy: Tovecimig Shows Promise for Biliary Tract Cancer!
2025-04-17
TL1A:Teva and Sanofi Announce Duvakitug Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
2025-02-10
IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
2025-01-17
Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
2025-01-17
GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy
2025-01-10
First 1 2 3 Last
Total 3 Page
Jump
Current position:News > News
classify
News
Genomeditech has officially secured global commercial usage rights for HEK293, Jurkat, and CHO-K1 cell lines
Genomeditech now holds global commercial usage rights for HEK293, Jurkat, and CHO-K1 cell lines. These widely used cell lines are essential for research and development in the biopharmaceutical industry. With clear traceability and legal compliance, Genomeditech is helping simplify authorization and accelerate commercialization. Learn more about the advantages and solutions we provide.
2026-06-03
cMET:U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
2025-05-15
FGF21:GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD
2025-05-15
FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
2025-04-25
GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
2025-04-25
DLL4 Breakthrough in Cancer Therapy: Tovecimig Shows Promise for Biliary Tract Cancer!
2025-04-17
TL1A:Teva and Sanofi Announce Duvakitug Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
2025-02-10
IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
2025-01-17
Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
2025-01-17
GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy
2025-01-10
MORE
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit